
Eye disease specialist Exonate appoints Hellebø as CEO
Biotechnology company Exonate has appointed Olav Hellebø as Chief Executive Officer. Exonate, which specialises in small-molecule therapeutics for patients with retinal vascular diseases, says Hellebø will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of… Read More



